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SUMMARY 19 
Background: Healthcare workers are at the forefront of the ongoing COVID-19 20 
pandemic and are at high risk for both the contraction and subsequent spread of virus. 21 
Understanding the role of anosmia as an early symptom of infection may improve 22 
monitoring and management of SARS-CoV2 infection.  23 
Methodology/Principal: We conducted a systematic review of the literature of SARS-24 
CoV2 infection/COVID-19 and anosmia to help inform management of anosmia in 25 
healthcare works. We report a case series of healthcare workers, who presented with a 26 
loss of sense of smell secondary to COVID-19 infection to demonstrate management 27 
principles. RT-PCR was used to confirm COVID-19 positivity and psychophysical 28 
testing of olfaction was performed using the British version of the University of 29 
Pennsylvania Smell Identification Test, UPSIT.  30 
Results: The systematic literature search returned 31 articles eligible for inclusion in 31 
the study and informed our recommendations for clinical assessment and management. 32 
All three healthcare professionals who presented with loss of sense of smell 33 
subsequently tested positive for SARS-CoV-2. Psychophysical testing of olfaction using 34 
the UPSIT confirmed mild and moderate microsmia in two, respectively, and 35 
normosmia at day 17 in one.  36 
Conclusions: Olfactory (+/- gustatory) dysfunction is indicative of COVID-19 infection 37 
and thus has important implications in the context of healthcare workers, or key 38 
workers in general, who work in close contact with others if not recognised as suffering 39 
from COVID. This leads to a potentially higher likelihood of spreading the virus. In 40 
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conjunction with our literature review these findings have helped with creating 41 
recommendations on the assessment and management of olfactory dysfunction during 42 
the ongoing COVID-19 pandemic, both for healthcare workers and patients.  43 
Key words: coronavirus, SARS-CoV-2, COVID-19, olfaction disorders, anosmia, 44 
pandemic, coronavirus infection 45 
 46 
INTRODUCTION 47 
Post Viral Olfactory Loss (PVOL) represents approximately 11% of cases of olfactory 48 
dysfunction in the community(1) but typically accounts for 20-25% of cases presenting 49 
to specialist clinics(2,3). Coronaviruses have previously been demonstrated to be among 50 
the respiratory viruses that can cause PVOL(4). Increasing number of reports of COVID-51 
19 positive patients describing a loss of smell and taste have been seen internationally 52 
since initial reports from China(5), Korea(6), Italy(7) and Iran(8). These may be the only 53 
symptoms, early presenting symptoms, or be part of mild flu-like symptoms(9,10). This 54 
topic has also received significant press coverage, especially with regard to potential 55 
public health implications - if anosmia is associated with COVID-19 symptomatology, 56 
patients experiencing these symptoms would also need to follow self-isolation guidance 57 
but as yet has not been added to the World Health Organisation list of official symptoms 58 
nor has it yet been recognised by Public Health England in the UK. It is known that the 59 
viral load is comparable between symptomatic and minimally 60 
symptomatic/asymptomatic individuals thus if people with anosmia were to have 61 
COVID-19, transmission is possible(11).  62 
 63 
The debate is ongoing as to what extent loss of smell and taste in SARS-CoV-2 64 
infection is caused by localised olfactory cleft oedema, architectural deformity of the 65 
olfactory neuroepithelium or direct neuroinvasion of the olfactory nerve pathways. In 66 
typical viral mediated olfactory loss, the pathophysiology involves loss of cilia of the 67 
olfactory sensory neurons(12). Furthermore, the loss of taste more likely reflects loss of 68 
flavour perception due to loss of retronasal olfaction rather than the loss of the sense of 69 
taste per se. 70 
 71 
There have been reports of increase in anosmia symptoms and a recent case report of 72 
anosmia in a healthcare worker in Madrid who was subsequently diagnosed with 73 
SARS-CoV-2. This raises questions regarding the significance of anosmia in COVID-74 
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19 - both generally in terms of anosmia management, but also of particular concern to 75 
healthcare workers, how to advise healthcare workers who present with such a symptom 76 
from a public health aspect in terms of isolation and testing.  77 
 78 
Here we present the results of a systematic review of the currently available literature 79 
on anosmia in COVID-19 and provide a summary table of the relevant findings. 80 
Secondly, we present three representative cases of healthcare workers presenting to our 81 
clinics with anosmia as their primary symptom of COVID-19. Finally, combining the 82 
findings from the review and the case series together, we provide recommendations on 83 
how to adapt existing anosmia management protocols in the context of COVID-19, 84 
particularly focussing on healthcare workers. 85 
 86 
SYSTEMATIC REVIEW OF THE LITERATURE  87 
A systematic literature search was performed on PubMed on 27 April 2020 using the 88 
following search terms: (((((((SARS-CoV-2) OR 2019-ncov) OR coronavirus) OR 89 
corona virus) OR COVID-19) OR COVID)) AND ((((((anosmia) OR hyposmia) OR 90 
loss of smell) OR smell) OR olfact*) OR cacosmia) OR dysosmia). We also screened 91 
BioRxiv and MedRxiv on for preprints related to anosmia in SARS-CoV-2. Inclusion 92 
criteria were papers describing reports of anosmia in patients in the context of COVID-93 
19, regardless of patient demographics, number of cases, and method of anosmia 94 
assessment. Date criteria were from 31/12/2019 to 27/04/2020. We hand searched citing 95 
literature and references of included studies. Papers that did not provide patient level 96 
data were not included for data extraction. We did not search for or include articles in 97 
the lay press or online forums. We also did not screen studies reporting general clinical 98 
features of anosmia as a recent review from The Centre for Evidence Based Medicine 99 
has assessed these studies already and found the evidence base was inconclusive(13). 100 
The authors did recommend incorporation of olfactory history and assessment in further 101 
studies. This conclusion was also reached by Lovato and colleagues who provide an 102 
overiew of upper respiratory tract symptoms in COVID-19 (14). Finally, any identified 103 
reviews were used to identify studies but were not themselves included in the data 104 
extraction. Data extraction included: number of patients, study method, onset of 105 
anosmia relative to COVID-19 symptoms, COVID-19 positivity and method of testing, 106 
time for recovery from anosmia, and summary findings. Formal evaluation and 107 




We found 107 unique papers of which 31 were eligible for inclusion in the study (Figure 110 
2). Summary findings of the included studies are in Supplemental Table 1 for reference. 111 
The 31 papers included work from multiple continents. The majority were cross 112 
sectional studies, case series or case reports. Diagnosis of smell dysfunction was 113 
variable and used a variety of published and custom designed self-reported surveys of 114 
anosmia/COVID-19 symptoms either in person, online, or via apps. Formal 115 
psychophysical testing of olfaction used the Nez-du-Vin, country specific UPSIT or the 116 
Sniffin’ Sticks.  117 
 118 
Anosmia is presenting as the primary symptom or as an early symptom in patients who 119 
have tested COVID+. In a European study, 11.8% of patients reported anosmia onset 120 
before other otorhinolaryngological symptoms(15). In the American Academy survey, 121 
26.6% reported it as an isolated initial symptom(16) and the Centre for Disease Control 122 
and Prevention has just added this to the symptoms related to COVID-19, but individual 123 
institutions may or may not be testing based on this symptom. Other surveys did not 124 
have a sufficient tested population. Thus, identifying olfactory dysfunction could 125 
potentially have a role in the diagnosis of COVID-19.  One study formally assessed 126 
smell and taste loss in a stepwise regression model and found them to be strongly 127 
associated with COVID-19. In fact it was the strongest predictor from a list of other 128 
symptoms and had a positive predictive value of 67%(17); the caveat of this study was 129 
that only 0.1% of all participants had been tested for COVID-19. Anosmia may also 130 
have potential to discriminate COVID-19 from other viral respiratory illnesses(18,19). 131 
 132 
Where anosmia is reported in the context of COVID-19, due to the short time that has 133 
elapsed since the pandemic started, data on the recovery of olfactory function is not 134 
always available. In the studies that have reported it in COVID-19 tested patients, albeit 135 
from surveys, complete resolution was seen in 13% and partial resolution in 14%, with 136 
a mean time to improvement of 7.2 days(16). This is lower than the recovery rates 137 
reported by Lechien and colleagues(15) who suggest a short term recovery rate of 44% 138 
in 59 patients who had clinically recovered from COVID-19, and also lower than the 139 
73% that reported by Levinson and colleagues(20), although only 15 patients make up 140 
this cohort. Recovery seems to take place within a few weeks but this may be due to 141 
short follow up and recovery may happen in others over a longer timeframe. The 142 
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coming months will begin to reveal whether COVID-19 will leave a larger burden of 143 
persistent PVOL patients in the community. 144 
 145 
Correlations suggested between disease mild severity disease and anosmia are 146 
necessarily preliminary. Whilst some suggestions are made that anosmia is associated 147 
with milder disease(21,22), this could be confounded by the inability to assess/self-report 148 
anosmia in those patients with severe disease in intensive care settings. However, a 149 
higher viral load, potentially indicative of more severe disease, does seem to be 150 
associated with a shorter duration of anosmia(23).  151 
 152 
Whether the underlying cause of anosmia is conductive or sensorineural was attempted 153 
to be addressed by two studies that assessed imaging of the olfactory system(24,25). 154 
Anosmia was found to be obstructive in nature rather than neural with a normal 155 
olfactory bulb. However, the presence of nasal obstructive symptoms (albeit 156 
subjectively reported) in patients with anosmia varied widely in the included studies. 157 
The reports of ACE2 receptor expression in non-neuronal cells and supporting olfactory 158 
sustentacular cells may support this finding (26-29). Alternatively, the virus could migrate 159 
from these cells if it were neurotropic(30,31). 160 
 161 
Healthcare workers suffering from anosmia were reported in multiple studies and in the 162 
American Academy data, approximately a third of patients were healthcare workers(16). 163 
Whilst this could be due to selection bias as only healthcare workers could enter data 164 
into the reporting tool, it suggests that both anosmia and COVID-19 in healthcare 165 
workers is an issue that is important to consider. Below, we present three illustrative 166 
cases to highlight issues to consider in the assessment and management of healthcare 167 
workers with anosmia.  168 
 169 
CASE SERIES 170 
Three healthcare professionals, a 43-year-old male nurse, a 37-year-old male Specialty 171 
Registrar in Rheumatology and a 53-year-old male Consultant Anaesthetist, presented 172 
to our ENT clinics with loss of their sense of smell and a history of other mild flu-like 173 
symptoms (Details in Table 1) in the last 3 weeks. In view of the emerging literature, 174 
we performed a COVID-19 real-time reverse transcription polymerase chain reaction 175 
(RT-PCR) swab test and confirmed COVID-19 infection. Formal assessment of their 176 
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olfactory function was performed using the British version of University of 177 
Pennsylvania Smell Identification Test (UPSIT), a validated psychophysical test in line 178 
with the guidelines in the Position paper on olfactory dysfunction(32). This confirmed 179 
moderate microsmia (UPSIT score of 25/40) in patient 1, mild microsmia (UPSIT score 180 
of 28/40) in patient 2 and the third patient told us that he felt that his sense of smell had 181 
already almost recovered at the time he was seen and he scored 34/40 on day 17. All 182 
three individuals were advised to contact occupational health for further advice, were 183 
given safety advice regarding his olfactory dysfunction, and referred to a website with 184 
validated patient information on their condition and guidance on olfactory training 185 
(www.fifthsense.org.uk).  186 
 187 
DISCUSSION AND RECOMMENDATIONS 188 
The presence of anosmia in the context of COVID-19 raises three main questions. 189 
Firstly, if a person develops isolated anosmia, what is the likelihood they already have, 190 
or will go on to develop, COVID-19? Secondly, what is the best strategy for treatment 191 
for anosmia in the context of COVID-19 and what is the prognosis for recovery of 192 
olfactory function? Finally, what is the underlying mechanism and pathophysiology of 193 
the anosmia? 194 
 195 
At present the answers to the above questions are limited until high-level robust 196 
evidence available. A global survey of COVID-19 related chemosensory impairment is 197 
currently underway: https://gcchemosensr.org.  198 
 199 
The mechanism at present is also debated with some suggesting the SARS-CoV-2 virus 200 
is neurotropic but others arguing the expression of target receptors in non-neuronal 201 
olfactory/nasal region cells suggests a possible inflammation with an obstructive cause 202 
of anosmia. There is also the possibility that acquired mutations of SARS-CoV-2 have 203 
enabled the virus to alter its pathogenicity and which may play a role in altering disease 204 
presentation(33). Nevertheless, the work presented here does highlight that anosmia in 205 
healthcare workers may be indicative of COVID-19. When combined with the 206 
preliminary evidence that anosmia is a strong diagnostic symptom, this has potentially 207 
important implications when anosmia is considered in the context of healthcare 208 
workers, or key workers in general. The ongoing potential contact with other people 209 
due to the nature of such professions means someone with COVID-19 is potentially at 210 
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higher likelihood both of contracting the virus and of spreading the virus if they were 211 
to catch it – anosmia may be an early symptom of this. There are limitations in the 212 
evidence presently available. The majority of studies are cross sectional or retrospective 213 
with limited prospective follow up. Many cases rely on self-reporting and COVID-19 214 
laboratory confirmed numbers are small. Where testing is performed, it relies on the 215 
RT-PCR test which the Centre for Evidence-Based Medicine reported to have as high 216 
as a 30% false-negative rate(34). Finally, formal assessment of anosmia varied with 217 
multiple survey types used and assessment modalities hence comparability and 218 
evidence synthesis are limited to comparable studies.  219 
 220 
Whilst the recent work by Hunter and colleagues(35) suggests that there is a comparable 221 
rate of COVID-19 positivity in frontline clinical staff compared with non-clinical staff 222 
in hospitals, the authors suggest this shows isolation and PPE measures are adequate at 223 
present to prevent nosocomial infections and the transmission may reflect that from the 224 
community. This is supported by a reduction coinciding with the UK wide lockdown 225 
timing. However, the authors only tested staff with new continuous cough and fever as 226 
per current PHE recommendations rather than staff screening for those with wider 227 
symptoms or if asymptomatic. Therefore, the work presented here is of relevance as it 228 
shows that testing may potentially need to be extended to a wider spectrum of 229 
symptoms, particularly if community transmission seems to be the prime vector. The 230 
other caveat is that a comparison with other institutions and control groups of non-231 
hospital key-workers would also be helpful.  232 
 233 
Our recommendations for the management of patients, particularly healthcare workers, 234 
with symptoms of hyposmia/anosmia during the COVID-19 crisis are guided by the 235 
Position Paper on Olfactory Dysfunction(3) and include: 236 
• Discussion regarding isolation and testing for COVID-19 with institutional 237 
occupational health service. 238 
• Full remote history asking about onset, duration, other COVID-19 symptoms, 239 
exposure risks, past otorhinolaryngological history, and general medical 240 
history.  241 
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• If no other red flag symptoms (such as facial pain, serosanguinous discharge, 242 
visual changes) and acute onset particularly in relation to flu-like symptoms 243 
during the COVID-19 pandemic, imaging (CT/MRI) is not indicated. 244 
• Ideally psychophysical testing(30,32) but this may be limited by resource and 245 
default to self-reporting, although individuals can be asked to self-test at home 246 
against common food cupboard items. Psychophysical testing, which can be 247 
done remotely (e.g. country specific UPSIT)(36) will avoid direct contact with 248 
patients. 249 
• Provide advice regarding safety precautions including need for gas alarm, 250 
smoke alarm, and care with use by dates for food. Patients can be directed to 251 
relevant online resources such as the Fifth Sense website. 252 
• Current guidance is to avoid oral steroids due to the potential risk of worsening 253 
COVID-19, as evidence from previous SARS in 2004 where systematic 254 
corticosteroids led to an increase in viral shedding(37). However, current trials, 255 
such as the RECOVERY trial for COVID-19 include systemic steroids in a 256 
treatment arm, so this advice may alter if these trials show evidence of benefit 257 
or at least no precipitation of deterioration in recipients. Intranasal steroids are 258 
unlikely to be harmful in patients already taking them but a fear of promoting 259 
viral shedding in new patients means advice currently is to avoid them. 260 
• Provide advice regarding olfactory training (e.g. from organisations such as 261 
Abscent/Fifth Sense). 262 
• Rhinology follow-up after crisis. Only consider an MRI olfactory protocol if 263 
there are any other concerning symptoms, but if there is a clear temporal history 264 
relating to the viral infection, especially where COVID+ve status is confirmed, 265 
an MRI scan is not indicated. 266 
 267 
National organisations in the UK and USA have recommended the addition of anosmia 268 
as a diagnostic symptom in the WHO criteria and potentially isolating if new onset 269 
anosmia is experienced as a symptom. Future work regarding the diagnostic utility and 270 
prognosis in large all-comer cohort studies with sufficient laboratory-based testing will 271 
hopefully provide stronger evidence for ongoing diagnosis and care of these patients. 272 
Until this time, we hope the evidence summary and recommendations in this work will 273 




CONCLUSIONS  276 
Loss of sense of smell and taste appears to be indicative of COVID-19 infection and 277 
has important implications in the context of healthcare workers, or key workers in 278 
general, who are in ongoing close contact with others due to their work. This leads to a 279 
potentially higher likelihood of contracting and spreading the virus. This literature 280 
review has helped to underline the clear link of loss of the senses of smell and taste 281 
during the ongoing COVID-19 pandemic, both for healthcare workers and patients. We 282 
hope our illustrative case series and recommendations can thus be applied to help 283 
manage these presentations of anosmia in the current climate until further evidence is 284 
available.  285 
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